Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02201420 · ClinicalTrials.gov registry record · Phase 2
Evaluation of Tc 99m Tilmanocept Localization in Primary Cutaneous Kaposi's Sarcoma and Lymphatic Drainage by SPECT/CT
A Phase 2 study, sponsored by Navidea Biopharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 5
- Enrollment target
NCT02201420: Completed Phase 2 study, sponsored by Navidea Biopharmaceuticals.
NCT02201420 is a Phase 2 study that has completed, run by Navidea Biopharmaceuticals. The registered enrollment target is 5 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (96% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02201420, a Phase 2 study, has completed, sponsored by Navidea Biopharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 5 participants
- Enrollment target
Study Summary
The purpose of this study (NAV3-12) is to determine the dissemination and localization of Tc 99m tilmanocept by SPECT and SPECT/CT imaging in subjects with confirmed cutaneous KS. This is a single center, open-label, within-subject study.
Primary Outcome
Count of subjects with a localization by Tc 99m tilmanocept by imaging. Localization is based on the use of SPECT imaging and defined as the accumulation of radioactivity at intensity greater than background.
Interventions
- DRUG Tc 99m tilmanocept
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2014-09 |
| Est. Completion | 2015-10 |
| Phase | Phase 2 |
What the finished NCT02201420 record still lists
NCT02201420 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 5 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (96% lower).
The record links to 0 conditions, and to 1 intervention - of which Tc 99m tilmanocept is the first listed.
NCT02201420 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02201420 about?
NCT02201420 is a clinical study titled "Evaluation of Tc 99m Tilmanocept Localization in Primary Cutaneous Kaposi's Sarcoma and Lymphatic Drainage by SPECT/CT". The purpose of this study (NAV3-12) is to determine the dissemination and localization of Tc 99m tilmanocept by SPECT and SPECT/CT imaging in subjects with confirmed cutaneous KS. This is a single center, open-label, within-subject study.
What is the current status of trial NCT02201420?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 5 participants. The study started on 2014-09. Estimated completion is 2015-10.
What interventions are being tested in trial NCT02201420?
The interventions under investigation include: Tc 99m tilmanocept (DRUG).
Who is sponsoring clinical trial NCT02201420?
This trial is sponsored by Navidea Biopharmaceuticals, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02201420's enrollment target sits among peer trials
5 2000th of 2000 the lowest of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia